The Outlook for Vaccines, Variants and Elusive Herd Immunity - Butler Financial, LTD
Navigating a sea of negativity - June 21, 2022

Resources

The Outlook for Vaccines, Variants and Elusive Herd Immunity

How do COVID-19 vaccines perform against the delta variant? When is FDA approval expected? And is herd immunity really achievable?

Raymond James Biotechnology Analyst Steve Seedhouse, Ph.D., addresses these questions and more in the latest episode of For What It’s Worth. Hear him discuss the latest data around vaccine effectiveness, the transition from pandemic to possible endemic and how COVID-prompted innovation may open the door for the prevention of other illnesses.

  
Listen to For What It's Worth on Spotify

Recorded August 3, 2021.


Other posts you might like
ButlerFinancial
Live by the numbers, die by the numbers

Economy & Policy July 01, 2022 Chief Economist Eugenio J. Alemán discusses current economic...

read more
ButlerFinancial
Weekly market guide

Markets & Investing July 01, 2022 Review the latest portfolio strategy commentary from Mike Gibbs,...

read more
ButlerFinancial
Translating market moves in challenging times

Markets & Investing July 01, 2022 Where can investors turn when the markets are a riddle? Raymond James...

read more